Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
China Pharma Univ. VDR compound D13
- Development stage
- Preclinical
- Lead developer
- China Pharmaceutical University
01
Overview
China Pharma Univ. VDR compound D13: sourced facts only. name: "Among 30 synthesized compounds, D13 exhibited strong VDR affinity and potent antifibrotic activity in vitro." [PMID:41779960]; target: "Among 30 synthesized compounds, D13 exhibited strong VDR affinity and potent antifibrotic activity in vitro." [PMID:41779960]; developer: "State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Drug Discovery for Metabolic Diseases, Center of Advanced Pharmaceuticals and Biomaterials, China Pharmaceutical University, Nanjing 211198, P. R. China." [PMID:41779960]; stage: "In a bile duct ligation mouse model, D13 significantly alleviated liver fibrosis without inducing hypercalcemia, unlike calcipotriol." [PMID:41779960]
02
Targets
VDR (Vitamin D receptor)
Beyond the preview
Go deeper on China Pharma Univ. VDR compound D13.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on China Pharma Univ. VDR compound D13.